Clinical Infectious Diseases · 1985 · 11 citations · 5 references
PharmacyInfectious DiseasesPharmacotherapyAntimicrobial PharmacologyAntimicrobial PharmacotherapyMedical MicrobiologyAntibiotic ResistanceAntimicrobial DosingCombination Antimicrobial TherapyPneumonia PharmacotherapyAcute Lower Respiratory Tract InfectionsBacterial Pneumonia TreatmentComparative Clinical TrialsInpatient Pneumonia TreatmentPneumonia Antibiotic TherapyRespiratory Bacterial Infections TreatmentRespiratory Infection TreatmentRespiratory Tract Infection Treatment
Aztreonam was administered to 226 patients with lower respiratory tract infections--primarily pneumonia (181 patients)--due to gram-negative bacilli. The clinical response rate was 93%, and the microbiologic cure rate was 78%. Most patients received 1-g or 2-g intravenous doses of aztreonam three times daily for at least five days. Ninety-eight of the 226 patients were involved in a randomized comparison of aztreonam with tobramycin; the latter drug was administered to a group of 34 patients. The overall microbiologic cure rates for the two drugs were 86% and 71%, respectively. Aztreonam is effective for the treatment of lower respiratory tract infections due to susceptible gram-negative bacilli.
5